This is what analysts have to say about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) after last week.

April 17, 2018 - By Dolores Ford

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) LogoInvestors sentiment decreased to 1.31 in Q4 2017. Its down 0.35, from 1.66 in 2017Q3. It fall, as 18 investors sold Neurocrine Biosciences, Inc. shares while 76 reduced holdings. 58 funds opened positions while 65 raised stakes. 91.25 million shares or 1.56% less from 92.69 million shares in 2017Q3 were reported.
Moreover, Driehaus Capital Management Limited Liability Co has 0.04% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Jpmorgan Chase & owns 542,579 shares. Pictet Asset Mgmt reported 1.12 million shares. 9,470 were reported by Ajo Limited Partnership. Verition Fund Management Limited Company accumulated 8,361 shares or 0.06% of the stock. Perceptive Advsr Ltd Liability Co invested in 13.25% or 5.15M shares. The Georgia-based Advisory Service Ltd Liability Corp has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Brown Brothers Harriman & has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Prelude Mgmt Ltd Liability Corporation invested 0.09% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Rmb Cap Mngmt Ltd Liability Co reported 57,277 shares stake. Artisan Partners Partnership holds 0.19% or 1.31M shares. Bb Biotech Ag, a Switzerland-based fund reported 3.45 million shares. Cubist Systematic Strategies Ltd Limited Liability Company owns 5,119 shares or 0.02% of their US portfolio. Legal General Group Public Ltd invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Fny Managed Accounts Ltd Liability Corp invested in 43 shares.

Since January 2, 2018, it had 0 buys, and 22 selling transactions for $29.59 million activity. Bozigian Haig P. had sold 1,625 shares worth $128,575. Another trade for 1,979 shares valued at $175,090 was sold by Lippoldt Darin. $79,863 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was sold by Lloyd-Smith Malcolm. On Friday, February 9 the insider Grigoriadis Dimitri E. sold $6.76 million. Gano Kyle sold $2.13M worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Monday, March 5. OBrien Christopher Flint had sold 2,613 shares worth $217,341.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 11 analysts covering Neurocrine (NASDAQ:NBIX), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine had 27 analyst reports since October 20, 2017 according to SRatingsIntel. As per Thursday, November 2, the company rating was maintained by Leerink Swann. Oppenheimer maintained it with “Buy” rating and $110.0 target in Tuesday, March 13 report. The rating was maintained by Robert W. Baird on Monday, October 23 with “Buy”. The firm has “Buy” rating given on Wednesday, October 25 by Piper Jaffray. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by BMO Capital Markets on Wednesday, November 1. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Overweight” rating given on Wednesday, February 14 by JP Morgan. The firm has “Buy” rating by Piper Jaffray given on Wednesday, March 14. Oppenheimer maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Wednesday, February 14. Oppenheimer has “Buy” rating and $100.0 target. The rating was maintained by Oppenheimer with “Buy” on Thursday, November 2. The stock has “Buy” rating by Cowen & Co on Friday, March 16. Below is a list of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) latest ratings and price target changes.

21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: Cowen & Co Rating: Buy New Target: $100.0 Maintain
14/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $113.0 Maintain
13/03/2018 Broker: Oppenheimer Rating: Buy New Target: $110.0 Maintain
22/02/2018 Broker: Oppenheimer Rating: Buy New Target: $110.0 Maintain
22/02/2018 Broker: Needham Rating: Buy New Target: $110.0 Maintain
20/02/2018 Broker: Leerink Swann Rating: Buy New Target: $96.0 Maintain
14/02/2018 Broker: Deutsche Bank Rating: Buy New Target: $97.0 Maintain
14/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $139.0 Maintain
14/02/2018 Broker: Oppenheimer Rating: Buy New Target: $100.0 Maintain

The stock increased 2.62% or $1.97 during the last trading session, reaching $77.27. About 488,246 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 91.92% since April 17, 2017 and is uptrending. It has outperformed by 80.37% the S&P500.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $6.95 billion. The companyÂ’s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womenÂ’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with ParkinsonÂ’s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: